Aprea Therapeutics (APRE) investor relations material

Executive summary

• Focused on precision oncology, developing targeted therapies for biomarker-defined cancers, with lead programs APR-1051 (WEE1 inhibitor) and ATRN-119 (ATR inhibitor).

• Accelerated enrollment and dose escalation in the Phase 1 ACESOT-1051 trial for APR-1051, targeting biomarker-defined cancers, with expansion from three to ten clinical sites.

• Updated Phase 1 data for APR-1051 presented at ASCO 2026 showed early clinical proof-of-concept, including confirmed partial responses and disease stabilization with manageable tolerability.

• Focus on advancing APR-1051 in uterine serous carcinoma, Cyclin E-overexpressing platinum-resistant ovarian cancer, and evaluating combination regimens in HPV-positive head and neck and colorectal cancers.

• ATRN-119 Phase 1/2a study closed; future development may focus on combination therapies.

Financial highlights

• Cash and cash equivalents at June 30, 2026: $41.2 million, up from $14.6 million at December 31, 2025.

• Net loss for Q2 2026: $3.6 million, or $(0.07) per share, compared to $3.2 million, or $(0.53) per share, in Q2 2025; net loss for six months ended June 30, 2026: $6.9 million, down from $7.2 million in 2025.

• Research and development expenses for Q2 2026: $2.5 million, up from $1.9 million in Q2 2025, mainly due to APR-1051 trial acceleration.

• General and administrative expenses stable at $1.6 million for Q2 2026.

• No grant revenue recognized in 2026 as NIH grants were exhausted.

Outlook and guidance

• Cash runway expected to fund operations and capital expenditures into Q1 2028 based on current plans.

• Next clinical data update for APR-1051 anticipated in Q4 2026 at a medical meeting; dose escalation and expansion expected to complete in Q2 2027.

• Ongoing efforts to expand clinical trial enrollment and explore combination strategies for APR-1051 and ATRN-119.